{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RARE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T01:26:34.504Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3749,"canonical_name":"Ultragenyx Pharmaceutical Inc.","cik":"0001515673","uei":null,"lei":null,"duns":null,"ticker":"RARE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":49,"clinical":3},"count":52,"timeline":[{"ts":"2026-10-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-10-14","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-421079","accession_number":"0001193125-26-421079","importance":35},{"ts":"2026-10-07","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-10-07","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-416251","accession_number":"0001193125-26-416251","importance":35},{"ts":"2026-10-02","kind":"clinical.trial","reporter":"Ultragenyx Pharmaceutical Inc","title":"MPS IIIA Disease Monitoring Program","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07855562","excerpt":"[\"MPS IIIA\",\"Sanfilippo Syndrome\",\"Sanfilippo A\",\"Mucopolysaccharidosis III\"]","importance":25},{"ts":"2026-09-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-09-17","url_slug":"/sec/cik-0001515673/8-k/0001515673-26-000006","accession_number":"0001515673-26-000006","importance":35},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Ultragenyx Pharmaceutical Inc. — 2026-09-15","url_slug":"/sec/cik-0001515673/144/0001950047-26-009497","accession_number":"0001950047-26-009497","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-09-15","url_slug":"/sec/cik-0001515673/4/0001193125-26-392233","accession_number":"0001193125-26-392233","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-09-08","url_slug":"/sec/cik-0001515673/4/0001193125-26-384878","accession_number":"0001193125-26-384878","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-09-02","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-380165","accession_number":"0001193125-26-380165","importance":35},{"ts":"2026-08-19","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-08-19","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-357185","accession_number":"0001193125-26-357185","importance":35},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-08-11","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-343525","accession_number":"0001193125-26-343525","importance":35},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Ultragenyx Pharmaceutical Inc. — 2026-08-07","url_slug":"/sec/cik-0001515673/schedule-13g/0000093751-26-000549","accession_number":"0000093751-26-000549","importance":55},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Ultragenyx Pharmaceutical Inc. — 2026-08-05","url_slug":"/sec/cik-0001515673/10-q/0001193125-26-333233","accession_number":"0001193125-26-333233","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-08-04","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-332802","accession_number":"0001193125-26-332802","importance":35},{"ts":"2026-08-04","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-08-04","url_slug":"/sec/cik-0001515673/4/0001193125-26-332536","accession_number":"0001193125-26-332536","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-08-04","url_slug":"/sec/cik-0001515673/4/0001193125-26-332547","accession_number":"0001193125-26-332547","importance":30},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Horn Howard","title":"Chief Financial Officer","shares":4696,"price_per_share":24.92,"usd_value":117024,"security_title":"Common Stock","importance":35.11702432},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Parschauer Karah Herdman","title":"EVP and Chief Legal Officer","shares":1900,"price_per_share":24.92,"usd_value":47348,"security_title":"Common Stock","importance":35.047348},{"ts":"2026-08-03","kind":"sec.filing","form_type":"144","title":"144 — Ultragenyx Pharmaceutical Inc. — 2026-08-03","url_slug":"/sec/cik-0001515673/144/0001950047-26-007510","accession_number":"0001950047-26-007510","importance":30},{"ts":"2026-07-31","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Ultragenyx Pharmaceutical Inc. — 2026-07-31","url_slug":"/sec/cik-0001515673/schedule-13g/0002100119-26-001487","accession_number":"0002100119-26-001487","importance":55},{"ts":"2026-07-31","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Ultragenyx Pharmaceutical Inc. — 2026-07-31","url_slug":"/sec/cik-0001515673/schedule-13g-a/0002100121-26-001001","accession_number":"0002100121-26-001001","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Ultragenyx Pharmaceutical Inc. — 2026-07-30","url_slug":"/sec/cik-0001515673/schedule-13g-a/0002012383-26-003116","accession_number":"0002012383-26-003116","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-07-06","url_slug":"/sec/cik-0001515673/4/0001193125-26-296128","accession_number":"0001193125-26-296128","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Horn Howard","title":"Chief Financial Officer","shares":4698,"price_per_share":33.13,"usd_value":155645,"security_title":"Common Stock","importance":35.15564474},{"ts":"2026-06-15","kind":"sec.form144","reporter":"KARAH PARSCHAUER","title":"Officer","shares":3799,"usd_value":92506,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006115","importance":40.01850113},{"ts":"2026-06-15","kind":"sec.form144","reporter":"CORAZON D. SANDERS","title":"Director","shares":2000,"usd_value":50100,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006073","importance":40.01002},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Sanders Corazon (Corsee) D.","title":null,"shares":2000,"price_per_share":25.05,"usd_value":50100,"security_title":"Common Stock","importance":35.0501},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Parschauer Karah Herdman","title":"EVP and Chief Legal Officer","shares":1899,"price_per_share":24.62,"usd_value":46753,"security_title":"Common Stock","importance":35.04675338},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Ultragenyx Pharmaceutical Inc. — 2026-06-15","url_slug":"/sec/cik-0001515673/144/0001950047-26-006073","accession_number":"0001950047-26-006073","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Ultragenyx Pharmaceutical Inc. — 2026-06-15","url_slug":"/sec/cik-0001515673/144/0001950047-26-006115","accession_number":"0001950047-26-006115","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-06-15","url_slug":"/sec/cik-0001515673/4/0001677455-26-000002","accession_number":"0001677455-26-000002","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-06-15","url_slug":"/sec/cik-0001515673/4/0001796536-26-000007","accession_number":"0001796536-26-000007","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"S-8","title":"S-8 — Ultragenyx Pharmaceutical Inc. — 2026-06-12","url_slug":"/sec/cik-0001515673/s-8/0001193125-26-269040","accession_number":"0001193125-26-269040","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"HOWARD HORN","title":"Officer","shares":4653,"usd_value":110602,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005347","importance":40.022120362},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Horn Howard","title":"Chief Financial Officer","shares":4653,"price_per_share":23.77,"usd_value":110602,"security_title":"Common Stock","importance":35.11060181},{"ts":"2026-05-18","kind":"sec.form144","reporter":"SHEHNAAZ SULIMAN","title":"Director","shares":5740,"usd_value":144189,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001950047-26-004713","importance":40.02883776},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"SULIMAN SHEHNAAZ","title":null,"shares":5740,"price_per_share":25.12,"usd_value":144189,"security_title":"Common Stock","importance":35.1441888},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Ultragenyx Pharmaceutical Inc. — 2026-05-18","url_slug":"/sec/cik-0001515673/8-k/0001193125-26-228639","accession_number":"0001193125-26-228639","importance":35},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Ultragenyx Pharmaceutical Inc. — 2026-05-18","url_slug":"/sec/cik-0001515673/144/0001950047-26-004713","accession_number":"0001950047-26-004713","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-05-18","url_slug":"/sec/cik-0001515673/4/0001713070-26-000002","accession_number":"0001713070-26-000002","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-05-18","url_slug":"/sec/cik-0001515673/4/0001796536-26-000004","accession_number":"0001796536-26-000004","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Ultragenyx Pharmaceutical Inc. — 2026-05-18","url_slug":"/sec/cik-0001515673/4/0001924797-26-000002","accession_number":"0001924797-26-000002","importance":30},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"WELCH DANIEL G","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"Dunsire Deborah","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"NARACHI MICHAEL","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"Fust Matthew K","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"Sanders Corazon (Corsee) D.","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"SULIMAN SHEHNAAZ","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.a","reporter":"Ray Amrit","title":null,"shares":7751,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Ultragenyx Pharmaceutical Inc. — 2026-05-12","url_slug":"/sec/cik-0001515673/schedule-13g/0000093751-26-000302","accession_number":"0000093751-26-000302","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"Ultragenyx Pharmaceutical Inc.","shares":5021441,"percent_of_class":5.1,"security_title":"SCHEDULE 13G","accession_number":"0000093751-26-000302","excerpt":null,"importance":55},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Ultragenyx Pharmaceutical Inc","title":"Long-term Extension of GTX-102 in Angelman Syndrome","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT06415344","excerpt":"[\"Angelman Syndrome\"]","importance":60},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Ultragenyx Pharmaceutical Inc","title":"Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT04360265","excerpt":"[\"Mucopolysaccharidosis IIIA\",\"MPS IIIA\",\"Sanfilippo Syndrome\",\"Sanfilippo A\"]","importance":60}]}